<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04944862</url>
  </required_header>
  <id_info>
    <org_study_id>CDX0159-04</org_study_id>
    <nct_id>NCT04944862</nct_id>
  </id_info>
  <brief_title>A Study of CDX-0159 in Patients With Prurigo Nodularis</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Single and Multiple Dose Study to Assess the Safety, Pharmacokinetics, and Clinical Effect of CDX-0159 in Patients With Prurigo Nodularis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celldex Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celldex Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to explore the safety, clinical effect, pharmacodynamics, and&#xD;
      pharmacokinetics of CDX-0159 in patients with Prurigo Nodularis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the study is to explore the safety, clinical effect, pharmacodynamics, and&#xD;
      pharmacokinetics of CDX-0159 in patients with Prurigo Nodularis.&#xD;
&#xD;
      There is a screening period of up to 2 weeks, an 8-week double-blind treatment period and a&#xD;
      16-week follow-up period after treatment. Patients will receive one or two doses of CDX-0159&#xD;
      or placebo.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability as assessed by the incidence and severity of adverse events</measure>
    <time_frame>From Day 1 (first dose) to Day 169 (last follow-up visit)</time_frame>
    <description>Safety and tolerability of multiple dose levels of CDX-0159 as determined by drug related adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic evaluation</measure>
    <time_frame>From Day 1 (before first dose) to Day 169 (last follow-up visit)</time_frame>
    <description>CDX-0159 serum concentrations will be measured at specified visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical effect of CDX-0159 on pruritus</measure>
    <time_frame>From Day 1 (first dose) to Day 57 (week 8)</time_frame>
    <description>The mean percent change from baseline to Week 8 in the weekly average score of worst intensity itch per a numeric rating scale. The Worst Itch-Numerical Rating Scale (WI-NRS) ranges from 0 = &quot;no itch&quot; to 10 =&quot;worst imaginable itch&quot; for their worst intensity prurigo nodularis itch in the preceding 24-hr period.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Prurigo Nodularis</condition>
  <arm_group>
    <arm_group_label>CDX-0159 1.5mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CDX-0159 1.5mg/kg administered intravenously every four weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CDX-0159 3mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CDX-0159 3.0 mg/kg administered intravenously once, followed by placebo four weeks later</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CDX-0159 4.5mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CDX-0159 4.5 mg/kg administered intravenously once, followed by placebo four weeks later</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline administered intravenously every four weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CDX-0159</intervention_name>
    <description>administered intravenously</description>
    <arm_group_label>CDX-0159 1.5mg/kg</arm_group_label>
    <arm_group_label>CDX-0159 3mg/kg</arm_group_label>
    <arm_group_label>CDX-0159 4.5mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>administered intravenously</description>
    <arm_group_label>CDX-0159 3mg/kg</arm_group_label>
    <arm_group_label>CDX-0159 4.5mg/kg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Males and females, 18 - 75 years old.&#xD;
&#xD;
          2. Diagnosis of Prurigo Nodularis by a dermatologist at least 3 months prior to Screening&#xD;
             with:&#xD;
&#xD;
               1. At least 20 PN nodules with bilateral distribution on both arms and/or both legs&#xD;
                  and/or both sides of the trunk at screening.&#xD;
&#xD;
               2. An Investigators Global Assessment (IGA) score for PN ≥ 3 at screening and&#xD;
                  Baseline (Day 1).&#xD;
&#xD;
          3. Severe itch, defined as the mean of the daily worst itch NRS (WI-NRS) score of ≥ 7&#xD;
             during the 7-day period immediately prior to initiation of study treatment.&#xD;
&#xD;
          4. Documented history of inadequate response to prescription topical medications or for&#xD;
             whom topical medications are medically inadvisable.&#xD;
&#xD;
          5. Willing to apply a topical moisturizer (emollient) twice daily throughout the study.&#xD;
&#xD;
          6. Both males and females of child-bearing potential must agree to use highly effective&#xD;
             contraceptives during the study and for 150 days afterwards after treatment.&#xD;
&#xD;
          7. Willing and able to complete a daily symptom electronic diary for the duration of the&#xD;
             study and adhere to the study visit schedule.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. PN due to neuropathy, psychiatric disorders or medications.&#xD;
&#xD;
          2. Unilateral lesions of prurigo (eg, only one arm affected)&#xD;
&#xD;
          3. Active unstable pruritic skin conditions in addition to PN.&#xD;
&#xD;
          4. Women who are pregnant or nursing.&#xD;
&#xD;
          5. Known hepatitis B or hepatitis C infection or active COVID-19 infection&#xD;
&#xD;
          6. Vaccination with a live vaccine within 2 months prior to study drug administration&#xD;
             (subjects must agree to avoid vaccination during the study and for four months&#xD;
             thereafter). NOTE: Inactivated vaccines are allowed such as seasonal influenza for&#xD;
             injection. COVID-19 vaccination is allowed.&#xD;
&#xD;
          7. History of anaphylaxis.&#xD;
&#xD;
        There are additional criteria that your study doctor will review with you to confirm you&#xD;
        are eligible for the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Celldex Therapeutics</last_name>
    <phone>844-723-9363</phone>
    <email>info@celldex.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Miami, Dermatology Clinical Trials Unit</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33125</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leigh Nattkemper</last_name>
      <phone>305-243-4472</phone>
      <email>Lxn202@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>Gil Yosipovitch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Olympian Clinical Research</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33614</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheryl O'Neill, BA, CCRC</last_name>
      <email>CONeill@OlympianResearch.com</email>
    </contact>
    <investigator>
      <last_name>Kelley Yokum, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 22, 2021</study_first_submitted>
  <study_first_submitted_qc>June 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 30, 2021</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CDX-0159</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prurigo</mesh_term>
    <mesh_term>Neurodermatitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

